Emcure Pharmaceuticals Ltd
NSE:EMCURE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (30.5), the stock would be worth ₹1 201.49 (28% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 42.2 | ₹1 664.6 |
0%
|
| 3-Year Average | 30.5 | ₹1 201.49 |
-28%
|
| 5-Year Average | 30.5 | ₹1 201.49 |
-28%
|
| Industry Average | 29.2 | ₹1 150.35 |
-31%
|
| Country Average | 23 | ₹905.5 |
-46%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
E
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
303.5B INR | 42.2 | 36.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 49.5 | 40.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 19.7 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 14.3 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 16.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 13 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.3 | 16.7 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Emcure Pharmaceuticals Ltd
Glance View
Emcure Pharmaceuticals Ltd. emerged as a prominent player in the Indian pharmaceutical landscape, guided by a commitment to innovation and accessibility. Founded in 1981 by Satish Mehta, the company started as a small-scale manufacturer and has since evolved into a global pharmaceutical powerhouse. Emcure thrives on a multifaceted business model that encompasses the complete pharmaceutical value chain, from research and development to manufacturing and distribution. The company's success rests on its robust portfolio of generics, branded generics, and biopharmaceuticals, which cater to diverse therapeutic areas like cardiology, oncology, gynecology, and infectious diseases. The driving force behind Emcure's financial engine is its ability to balance volume and value. Through a network of state-of-the-art facilities, Emcure sustains a strong presence both domestically and internationally, with exports spanning over 70 countries. The firm capitalizes on economies of scale by leveraging its extensive production infrastructure, allowing it to offer high-quality medications at competitive prices. Furthermore, strategic collaborations and licensing agreements empower Emcure to penetrate new markets and broaden its product offerings. By continually expanding its pipeline and embracing cutting-edge technologies, Emcure not only secures its position in the competitive pharmaceutical industry but also reinforces its mission to deliver affordable healthcare solutions globally.
